+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Sildenafil versus nitric oxide for acute vasodilator testing in pulmonary arterial hypertension

Sildenafil versus nitric oxide for acute vasodilator testing in pulmonary arterial hypertension

Pulmonary Circulation 5(2): 305-312

Vasoreactivity testing with inhaled NO is recommended for pulmonary arterial hypertension (PAH) because of its therapeutic and prognostic value. Sildenafil has acute pulmonary vasodilating properties, but its diagnostic and prognostic impact in PAH is unknown. Our objective was to compare acute vasodilating responses to sildenafil and those to NO during right heart catheterization and also their prognostic values in patients with PAH. Ninety-nine patients with idiopathic PAH and 99 with associated PAH underwent vasoreactivity testing with NO and sildenafil. Only mild adverse effects of sildenafil, in the form of hypotension, were observed, at a rate of 4.5%. The acute responder rate was 8.1% for NO and 11.6% for sildenafil. The NO-induced response in mean pulmonary arterial pressure and cardiac output correlated with the response to sildenafil. Thirteen patients were long-term responders to calcium channel blockers (CCBs), and 3 of them were correctly identified by acute vasoreactivity test with both drugs. The specificity of the vasoreactivity test for identifying long-term CCB responders was 88.9% for NO and 85.1% for sildenafil testing. A trend toward better survival was found in sildenafil and NO responders, compared with nonresponders. Use of sildenafil for vasoreactivity testing is safe. Sildenafil may be useful as alternative vasoreactivity-testing agent, identifying the same number of long-term CCB responders as NO. However, NO seems to be a more ideal testing drug because of its pharmacologic properties. Moreover, sildenafil vasoreactivity testing might contribute to an improved estimate of prognosis among patients with PAH.

(PDF emailed within 0-6 h: $19.90)

Accession: 058851877

Download citation: RISBibTeXText

PMID: 26064455

DOI: 10.1086/680355

Related references

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation 105(20): 2398-2403, May 21, 2002

Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. American Journal of Cardiology 90(6): 677-680, 2002

Sildenafil is a pulmonary vasodilator which augments and prolongs vasodilatation by inhaled nitric oxide in patients with pulmonary hypertension. Circulation 100(18 SUPPL ): I 240, Nov 2, 1999

Acute vasodilator testing with oral high-dose calcium channel-blockers in primary pulmonary hypertension Comparison with nitric oxide. European Respiratory Journal 8(SUPPL 19): 195S, 1995

Sildenafil reduces pressure and pulmonary resistance and increases susceptibility of pulmonary arteries to nitric oxide in primary pulmonary arterial hypertension. Przeglad Lekarski 62(2): 135-138, 2005

Nitric Oxide Attenuates Arterial Pulse Wave Reflection in a Vasodilator Responding Pulmonary Arterial Hypertension Patient. Circulation. Cardiovascular Interventions 11(3): E006242-E006242, 2018

Vasodilator testing with nitric oxide and/or oxygen in pediatric pulmonary hypertension. Pediatric Cardiology 31(5): 598-606, 2010

Acute pulmonary vasodilator testing with inhaled treprostinil in children with pulmonary arterial hypertension. Pediatric Cardiology 34(4): 1006-1012, 2013

Acute pulmonary vasodilator testing is a critical step in the management of patients with pulmonary arterial hypertension. Zhonghua Jie He He Hu Xi Za Zhi 31(5): 378-380, 2008

Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. Journal of the American College of Cardiology 33(3): 813-819, 1999

Acute vasodilator testing in idiopathic pulmonary arterial hypertension: must we take NO for the answer?. European Respiratory Journal 33(6): 1247-1249, 2009

Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension. American Journal of Physiology. Lung Cellular and Molecular Physiology 290(4): L723-L729, 2005

Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents. Clinics in Perinatology 39(1): 149-164, 2012

Stimulation of soluble guanylate cyclase attenuates acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide. FASEB Journal 18(4-5): Abst 688 14, 2004

Oral sildenafil is an effective specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Acc Current Journal Review 11(6): 20-0, 2002